You are here: Home News PhinC joins the GamaMabs steering committee

PhinC joins the GamaMabs steering committee

PhinC Development is pleased to announce its participation at the GamaMabs steering committee.

GamaMabs Pharma is a biotechnology company based in Paris and Toulouse (France).GamaMabs develops innovative monoclonal antibodies against gynaecologic cancers. GamaMabs’ lead project is the first-in-class monoclonal antibody (mAb) GM102 (formerly known as 3C23K), currently in pre-IMPD stage.

We hope that our participation will provide all the helpful advices GamaMabs expects for the next steps of drug development. According to our expertise, we particularly guide strategies regarding the transition between preclinical and First-in-Man studies, and then the early clinical development steps.